Effectiveness and Safety of #Apixaban Compared With #Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study

Apixaban and rivaroxaban are the most commonly prescribed direct oral anticoagulants for adults with atrial fibrillation, but head-to-head data comparing their safety and effectiveness are lacking.. 39 351 patients newly prescribed apixaban were propensity score matched to 39 351 patients newly prescribed rivaroxaban. Mean age was 69 years, 40% of patients were women, and mean follow-up was 288 days for new apixaban users and 291 … Continue reading Effectiveness and Safety of #Apixaban Compared With #Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study

#Rivaroxaban Versus Vitamin K Antagonist in #Antiphospholipid Syndrome: A Randomized Noninferiority Trial

After 3 years of follow-up, recurrent thrombosis occurred in 11 patients (11.6%) in the rivaroxaban group and 6 (6.3%) in the VKA group (RR in the rivaroxaban group, 1.83 [95% CI, 0.71 to 4.76]). Stroke occurred more commonly in patients receiving rivaroxaban (9 events) than in those receiving VKAs (0 events) (corrected RR, 19.00 [CI, 1.12 to 321.9]). Major bleeding occurred in 6 patients (6.3%) … Continue reading #Rivaroxaban Versus Vitamin K Antagonist in #Antiphospholipid Syndrome: A Randomized Noninferiority Trial